We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $633M
1-Year Est. Return 173.22%
This Fund
S&P 500
This Quarter Est. Return
+71.69%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$388M
AUM Growth
+$134M
Cap. Flow
-$4.71M
Cap. Flow %
-1.21%
Top 10 Hldgs %
96.84%
Holding
17
New
2
Increased
7
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$15.2M
2
GHRS icon
GH Research
GHRS
+$11.7M
3
SLN
Silence Therapeutics
SLN
+$6.32M
4
PASG icon
Passage Bio
PASG
+$5.37M
5
STOK icon
Stoke Therapeutics
STOK
+$4.48M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$46.1M
2
AUTL
Autolus Therapeutics
AUTL
+$2.92M
3
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$2.84M
4
CABA icon
Cabaletta Bio
CABA
+$589K
5
PVLA
Palvella Therapeutics
PVLA
+$173K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
1
DELISTED
Alpine Immune Sciences Inc
ALPN
$89.3M 23.01%
2,253,183
-1,560,743
-41% -$46.1M
MRUS
2
DELISTED
Merus
MRUS
$68M 17.5%
1,509,007
+373,782
+33% +$15.2M
STOK icon
3
Stoke Therapeutics
STOK
$1.82B
$49.9M 12.85%
3,696,820
+739,902
+25% +$4.48M
TCRX icon
4
TScan Therapeutics
TCRX
$51.9M
$41.5M 10.68%
5,224,600
– –
CABA icon
5
Cabaletta Bio
CABA
$439M
$35.5M 9.15%
2,082,973
-27,428
-1% -$589K
GHRS icon
6
GH Research
GHRS
$1.87B
$35.3M 9.09%
3,310,563
+1,471,946
+80% +$11.7M
CCCC icon
7
C4 Therapeutics
CCCC
$376M
$29.7M 7.65%
3,634,662
+500,266
+16% +$3.88M
SLN
8
Silence Therapeutics
SLN
$521M
$11.4M 2.93%
526,642
+290,855
+123% +$6.32M
AUTL
9
Autolus Therapeutics
AUTL
$386M
$8.87M 2.28%
1,390,160
-468,249
-25% -$2.92M
PASG icon
10
Passage Bio
PASG
$15.9M
$6.54M 1.69%
242,294
+223,336
+1,178% +$5.37M
KNTE
11
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$5.27M 1.36%
1,981,106
-15,900
-0.8% -$39.4K
IBIO icon
12
iBio
IBIO
$71M
$2.44M 0.63%
+600,000
New +$754K
NKTR icon
13
Nektar Therapeutics
NKTR
$2.39B
$1.93M 0.5%
137,923
+9,310
+7% +$97.5K
PVLA
14
Palvella Therapeutics
PVLA
$1.98B
$1.61M 0.41%
109,740
-12,458
-10% -$173K
NEUP
15
Neuphoria Therapeutics
NEUP
$19.7M
$839K 0.22%
67,872
-820
-1% -$10.8K
CNTA
16
DELISTED
Centessa Pharmaceuticals
CNTA
$197K 0.05%
+17,400
New +$165K
THRX
17
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-702,415
Closed -$2.84M

Similar funds

SWM
SilverOak Wealth Management Edina, Minnesota $632M AUM 18.6% 1-Year Est. Return
RFA
Rollins Financial Advisors New York City, New York $632M AUM 23.84% 1-Year Est. Return
WA
WFM Asia Road Town, Tortola, British Virgin Islands $632M AUM 14.51% 1-Year Est. Return
AMM
American Money Management Rancho Santa Fe, California $632M AUM 14.06% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $634M AUM
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return

Lynx1 Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Lynx1 Capital Management held 17 positions worth $388M, up 53% from $254M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Lynx1 Capital Management's Q1 2024 filing shows 2 new, 7 increased, 6 reduced and 1 closed positions. Its largest new stake was iBio: 600,000 shares worth $2.44M. The largest sale was Alpine Immune Sciences Inc, an estimated $46.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Lynx1 Capital Management's largest Q1 2024 buy was iBio: 600,000 shares worth $2.44M.
  • Lynx1 Capital Management added most to Merus in Q1 2024, an estimated $15.2M increase.
  • Lynx1 Capital Management's biggest Q1 2024 reduction was Alpine Immune Sciences Inc, cutting an estimated $46.1M.
  • Lynx1 Capital Management fully exited Theseus Pharmaceuticals, Inc. Common Stock in Q1 2024, selling an estimated $2.84M.
  • Lynx1 Capital Management's ten largest holdings make up 97% of its $388M portfolio in Q1 2024.
  • Lynx1 Capital Management opened 2 new positions and closed 1 in Q1 2024.
  • Lynx1 Capital Management's portfolio value rose 53% quarter-over-quarter to $388M.

Based on Lynx1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.